Related Experiment Video
Updated: Jun 21, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Glucose control: how low should you go with the critically ill?
Adam J Zolotor1, Sarah-Anne Schumann, Lisa Vargish
1Department of Family Medicine, University of North Carolina, Chapel Hill, NC USA.
The Journal of Family Practice
|August 15, 2009
Summary
For intensive care unit (ICU) patients with hyperglycemia, a blood glucose target of 180 mg/dL is recommended over 81-108 mg/dL. Aggressively lowering glucose levels in these patients may increase mortality risk.
Area of Science:
- Critical Care Medicine
- Endocrinology
- Metabolic Disorders
Background:
- Hyperglycemia is common in critically ill patients.
- Current guidelines suggest varying glycemic targets for ICU patients.
- The optimal blood glucose level for ICU patients remains a topic of research.
Discussion:
- This study challenges the conventional, more stringent blood glucose targets for ICU patients.
- It suggests that a less aggressive approach to glucose control may be safer.
- The findings highlight the potential risks associated with overly intensive glycemic management.
Key Insights:
- The recommended blood glucose target for hyperglycemic ICU patients is less than or equal to 180 mg/dL.
- Blood glucose levels between 81 to 108 mg/dL are associated with increased mortality in this population.
- Intensive glucose-lowering strategies may confer a higher risk of death.
Outlook:
- Further research is needed to confirm these findings in diverse patient populations.
- Clinical practice guidelines for glycemic control in the ICU may require revision.
- This study could influence future therapeutic strategies for managing hyperglycemia in critical care settings.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...